3 Dividend Stocks to Buy and Hold Forever (Including 1 Dividend King)

The article highlights three dividend-focused “buy and hold forever” candidates—AbbVie, Enbridge, and Realty Income—emphasizing long dividend growth streaks (AbbVie: 53 years; Enbridge: 31 years; Realty Income: 31 years and 674 consecutive months) and recession-resilient business models. For AbbVie, it points to a $10.9B acquisition of Apogee Therapeutics to expand its immunology pipeline following Humira’s patent expirations, while Enbridge is framed as targeting ~5% CAGR in distributable cash flow/earnings/EBITDA supported by data center, LNG, onshoring, and coal-to-gas trends. Overall tone is constructive for long-term total returns (notably Enbridge’s ~5.6% yield), but it is primarily stock-picking commentary with limited near-term market-moving implications.

Analysis

ABBV is less a "dividend story" than a self-funded pipeline compounding machine: the market tends to re-rate these names when management proves it can recycle mature cash flows into new assets without blowing up leverage. The Apogee transaction is useful mainly as a signal that immunology remains strategically valuable; it should support sentiment around the category more than it moves near-term EPS. Second-order, that keeps bid expectations elevated for smaller inflammation assets and may lift the perceived floor under APGE-like biotech names, but it also raises the bar for proof that ABBV can keep replacing patent-cliff growth internally.

ENB is the cleanest structural beneficiary in the group because its economics are tied to molecule throughput, not commodity direction. The underappreciated angle is load growth: data centers and LNG both convert power-demand growth into a need for firm gas infrastructure, which supports utilization and fee-based cash flow even if oil prices stall. The main falsifier over 1-3 months is a slowdown in capital commitments or regulatory friction on new pipes; over 6-18 months, higher rates can still compress infrastructure multiples even if fundamentals stay intact.

O is the most rate-sensitive of the three, so the stock is really a duration trade wrapped in a dividend. If Treasury yields fall, the acquisition pipeline and European expansion can translate into a decent total-return setup; if yields back up, "dividend safety" will not prevent multiple compression. Consensus is probably overconfident that stable rent collection equals low volatility; in reality, the valuation hinge is financing cost and cap-rate discipline, not occupancy.

Key Decisions for Investors

• Long ABBV on pullbacks; treat it as a cash-flow compounder, not a growth chase. Risk/reward works best if management keeps leverage contained and post-Humira growth remains intact over the next 1-2 earnings cycles.
• Overweight ENB versus rate-sensitive utilities as a 6-18 month infrastructure/gas-throughput play. Entry is best on any 3-5% pullback tied to rate volatility; thesis breaks if DCF growth guidance rolls over or permitting delays intensify.
• Use O as a tactical buy only when long rates are trending lower; otherwise keep it on a watchlist. Consider a call-spread structure if the 10Y yield backs off, since upside is mostly multiple expansion rather than operating surprise.
• Watch APGE and the broader biotech M&A basket for follow-on bid premium, but do not chase here unless the spread widens or a second strategic buyer emerges. The read-through is sentiment, not near-term fundamentals.
• If you want a relative-value expression, pair long ENB with short XLU: ENB has more explicit volume growth from gas/LNG trends, while XLU is more exposed to duration and regulated-return compression if rates stay elevated.